Top Clinical Chemistry Researcher Warns of Faulty Antibodies Infiltrating US, European Markets | GenomeWeb

Antibody quality has long loomed as a significant concern for proteomics research, with much discussion in the field of what validation steps are needed and what data vendors should provide to ensure the performance of a given affinity agent.

According to Nader Rifai, director of clinical chemistry at Children's Hospital Boston and the editor-in-chief of the journal Clinical Chemistry, these concerns have recently taken on a new urgency due to the appearance on the market of a large number of faulty antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.